Creative Medical Technology Holdings (CELZ) Assets Average (2011 - 2026)
Creative Medical Technology Holdings' (CELZ) quarterly Assets Average came in at $7.9 million in Q2 2026, up 2.37% year-over-year from $7.7 million in Q2 2025, and up 11.0% quarter-over-quarter from $7.1 million in Q1 2026.
Analysis
Creative Medical Technology Holdings (CELZ) Assets Average (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Assets Average for 16 consecutive years, with $7.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Assets Average rose 2.37% year-over-year to $7.9 million in Q2 2026; TTM through Jun 2026 was $7.9 million, a 2.37% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, down 16.71% from the prior year.
- Assets Average was $7.9 million for Q2 2026 at Creative Medical Technology Holdings, up from $7.1 million in the prior quarter.
- Over five years, Assets Average peaked at $23.0 million in Q3 2022 and troughed at $6.5 million in Q3 2025.
- A 5-year average of $11.4 million and a median of $9.5 million in 2024 frame the typical range for Assets Average.
- Across the five-year window, Assets Average jumped 1967.6% in 2022 and plunged 44.23% in 2023, its largest moves.
- Over 5 years, Assets Average stood at $20.8 million in 2022, then sank by 44.23% to $11.6 million in 2023, then sank by 41.64% to $6.8 million in 2024, then climbed by 0.78% to $6.8 million in 2025, then advanced by 15.78% to $7.9 million in 2026.
- The last three Assets Average figures came in at $7.9 million (Q2 2026), $7.1 million (Q1 2026), and $6.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 1.45 Bn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 2.69 Bn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 920.60 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.67 Bn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 881.90 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 1.43 Bn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 154.46 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.18 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 494.25 Mn |
| 10 | Creative Medical Technology Holdings | 1.45 Mn | 1.45 Mn | - | 7.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.91 Mn |
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Sep 30, 2025 | 6.48 Mn |
| Jun 30, 2025 | 7.73 Mn |
| Mar 31, 2025 | 7.51 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | 7.44 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | 10.17 Mn |
| Dec 31, 2023 | 11.61 Mn |
| Sep 30, 2023 | 13.32 Mn |
| Jun 30, 2023 | 14.68 Mn |
| Mar 31, 2023 | 17.21 Mn |
| Dec 31, 2022 | 20.83 Mn |
| Sep 30, 2022 | 22.95 Mn |
| Jun 30, 2022 | 16.58 Mn |
| Mar 31, 2022 | 10.50 Mn |
| Dec 31, 2021 | 7.20 Mn |
| Sep 30, 2021 | 1.93 Mn |